Lv64
2860 积分 2024-01-29 加入
A Review on Medicinal Approaches of Novel Imatinib Derivatives
1个月前
已完结
Oncopharmacological aspects of Bcr-Abl inhibitors: from revolutionary structure-based design to clinical resistance
1个月前
已完结
Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization
2个月前
已完结
Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy
2个月前
已完结
A Radioligand Competition Binding Protocol for Assessing the Association and Dissociation Rates of Unlabeled Compounds
2个月前
已关闭
Association of PD-L1 expression and clinical outcomes in ROS1-rearranged advanced non-small cell lung cancer treated with entrectinib
4个月前
已完结
Progressive metastatic infantile fibrosarcoma with multiple acquired mutations
6个月前
已关闭
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)
7个月前
已关闭
Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling
7个月前
已完结
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
7个月前
已完结
皖公网安备34019202002308
